OBJECTIVES: When studying HIV infection, administrative claims databases can provide information on treatment and cost for large numbers of patients but most do not contain laboratory test results, making it impossible to know when a change in antiretroviral treatment (ART) was due to virologic failure. Our objective was to develop and validate a model for identifying patients in a claims database who switched ART due to virologic failure. METHODS: We identified three databases of adult HIV-positive patients who switched ART regimens between January 1, 2003 and March 31, 2008. The HIV Insight clinical registry was used to develop a logistic regression model incorporating demographics, regimen characteristics, and other independent variables to estimate the odds of virologic failure. Next, the subset of the Ingenix i3 LabRx health insurance claims database with HIV viral load test results (claims/lab database) was used to validate the model. The model was then used to estimate the proportion of patients with virologic failure in the full Ingenix i3 LabRx claims database (claims database). RESULTS: There were 1,691 patients with ART switches in HIV Insight; 1,073 in the claims/lab database, and 3,954 in the claims database. The base model (main effects only) had good discriminatory ability (c = 0.875); but poor overall model fit (Hosmer Lemeshow test, p < 0.001). Adding three significant two-way interaction terms improved fit (p = 0.8692) and discriminatory ability (c = 0.885). When the final model was applied to the claims/lab database, it predicted 18.9% of patients would have virologic failure; the actual proportion was 18.6%. CONCLUSIONS: We developed and validated a model that could be used in administrative claims to predict the proportion of ART switches due to virologic failure. Health plans may use this model to identify treatments with rising rates of virologic failure and to examine costs related to such failure. OBJECTIVES: Prices of recently launched monoclonal antibodies are high and their accessibility differs across Europe. Trastuzumab (TRZ) was recommended by payers for early and advanced breast cancer (BC) in Europe, with differences in the process and timelines of recommendations. Cetuximab (CTX) for metastatic colorectal cancer
DB2 EVALUATION OF AGREEMENT BETWEEN INTERNET-BASED SELF-AND PROXY-REPORTED HEALTH CARE UTILIZATION AND ADMINISTRATIVE HEALTH CARE CLAIMS
Palmer L 1 , Johnston SS 1 , Rousculp M 2 , Nichol KL 3 , Mahadevia PJ 2 1 Thomson Reuters, Washington, DC, USA, 2 MedImmune, Gaithersburg, MD, USA, 3 University of Minnesota, Minneapolis, MN, USA OBJECTIVES: Mode of survey administration is an important determinant of the validity/accuracy of self-reported, health care utilization (HCRU). While Internetbased surveys are becoming more common, little is known about agreement between administrative claims data and Internet-based survey self-and proxy-reported HCRU. This analysis evaluated the level of agreement of self-and proxy-reported HCRU as recorded through an Internet-based survey as compared to administrative claims-based HCRU data from three large self-insured U.S. employers. METHODS: Monthly Internet-based surveys of employees (n = 2,298) in the Child and Household Influenza-Illness and Employee Function Study were captured 11/07-5/08. The survey captured data on the presence and number of visits to hospitals, emergency departments, urgent care centers and office visits for employees' care and for household member (HHM) care (n = 6,884). Administrative claims from the Marketscan® Databases were assessed during the same time period and evaluated relative to the survey-based HCRU metrics. Only data for individuals with employer-sponsored health care coverage and who could be linked to the claims data using via direct matching was included (n = 5,718, 62%). The Kappa (κ) statistic was used to evaluate visit concordance and correlation statistics were used to describe frequency consistency. RESULTS: There was moderate to substantial visit presence and frequency agreement between surveybased and claims-based HCRU for all service categories. Percent agreement for presence of a particular service ranged from 99.2% (inpatient stay, κ = 0.71) to 76.4% (outpatient visits, κ = 0.52). The correlation in the survey-based and claims-based visit frequency for inpatient, emergency department, urgent care center and outpatient visits was 0.59, 0.66, 0.42 and 0.61 respectively (all p < 0.001). Visit presence and frequency agreement was similar for self-and proxy-reported HCRU. CONCLUSIONS: Relative to previously published HCRU metrics elicited from paper and telephony survey methods, this study's agreement values suggest that Internet-based surveys are an effective method to collect self-and proxy-reported HCRU.
DB3

MUCH ADO ABOUT THE LACK OF SOCIO-ECONOMIC COVARIATES IN ADMINISTRATIVE CLAIMS DATA Borah B
Mayo Clinic, Rochester, MN, USA OBJECTIVES: Administrative claims data from managed care plans are often used to assess health care utilization and cost. However, a major criticism against the use of claims data is that they often lack socio-economic-status (SES) information including race, years of education, marital status and household income. Therefore, claims-based estimates of utilization and cost measures may be biased. Using Medical Expenditures Panel Survey (MEPS), this paper shows that the SES factors may not have significant bearing on the predicted utilization and cost measures. METHODS: The 2007 MEPS data were used for this study. In order to make the study sample resemble a typical sample from claims data from a managed care plan, MEPS patients aged between 18 and 65 years enrolled in a managed care plan throughout 2007 were included in the final sample. Overall and pharmacy costs were analyzed using generalized linear modeling (GLM) with gamma distribution and log link while the number of office and outpatient visits were modeled using GLM with Poisson distribution and log link. Each regression was run with and without the four SES variables, and the resulting predicted values were compared. RESULTS: The predicted number of office and outpatient visits with SES covariates in the GLM regression equation were 2.81(SD = 1.92) and 0.43(SD = 0.65), and without SES covariates were 2.83(SD = 1.91) and 0.41(SD = 0.61). Similarly, the predicted pharmacy and total health care cost with SES covariates were $897(SD = $1,562) and $3,990(SD = $4,697), and without SES covariates were $854(SD = $1,334) and $4,101(SD = $4,633). Thus, predicted utilization and cost measures with or without the SES variables in the corresponding GLM regression were not statistically different. CONCLUSIONS: Our results reject the hypothesis that the lack of SES covariates in claims data might result in biased estimates of utilization and cost. Further investigation is warranted to check the robustness of the model specifications for utilization and cost.
DB4 ACCOUNTING FOR THE RELATIONSHIP BETWEEN PER DIEM COST AND LOS WHEN ESTIMATING HOSPITALIZATION COSTS
Stolar M 1 , Hu MY 2 , Ishak K 3 , Wang Y 2 , Williams GC 2 , Ferguson J 2 , Getsios D 4 , Alvarez P 1 1 United BioSource Corporation, Lexington, MA, USA, 2 The Medicines Company, Parsippany, NJ, USA, 3 United BioSource Corporation, Dorval, QC, Canada, 4 United BioSource Corporation, Halifax, NS, Canada OBJECTIVES: Hospitalization costs in trials are often derived using observed lengths of stay (LOS) and fixed per diem costs obtained from supplemental data sources. This approach assumes per diem costs are independent of LOS, which is generally not the case. We sought to develop an approach that accounts for this relationship to obtain more accurate cost estimates. METHODS: To examine the association between perioperative blood pressure control and hospitalization costs for coronary artery bypass graft (CABG), valve surgery or combined surgeries, data from the Massachusetts Acute Hospital Case Mix Database for 2005-2007 were used to derive LOS-specific per diem costs. Regression analyses were carried out to model this relationship, allowing for non-linear functional forms. Costs were log-transformed to account for their skewed distributions. Exploratory analyses were carried out to identify suitable parameterizations and candidate models were compared using goodness-of-fit statistics. Complications occurring during hospitalization were included as predictors of per diem costs with a possible interaction with LOS. For illustrative purposes we present results for patients undergoing CABG. RESULTS: The Massachusetts database yielded 10,601 patients undergoing CABG. Mean ± SD LOS was 9.47 ± 5.86 days and per diem cost was $6,241 ± $3,019. Per diem costs varied across different complications and LOS. Per diem costs were highest for patients who died in-hospital and those with multiple complications. Per diem costs were high for short LOS, then declined steadily to LOS of 14 days, and were relatively constant thereafter, showing a linear relationship between log per diem costs and log LOS. This model had considerably better fit compared to one that assumed a single per diem cost (Akaike Information Criterion 7,825 vs. 10,440, respectively). CONCLUSIONS: Mean per diem costs depend highly on the LOS of the hospitalization. Accounting for the relationship between per diem cost and LOS yields better estimates of costs and subsequent inferences.
PODIUM SESSION I: HEALTH CARE EXPENDITURES STUDIES
HE1 COST-EFFECTIVENESS OF 1ST LINE CHEMOTHERAPY REGIMENS IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER AMONG PATIENTS RECEIVING CARE IN THE OUTPATIENT COMMUNITY SETTING
Hoverman JR 1 , Pohl G 2 , Gruschkus SK 3 , Marciniak M 2 , Forsyth M 3 , Peltz G 2 1 Texas Oncology, Dallas, TX, USA, 2 Eli Lilly and Company, Indianapolis, IN, USA, 3 Healthcare Informatics, The Woodlands, TX, USA OBJECTIVES: To evaluate the incremental cost-effectiveness of combination pemetrexed/platinum chemotherapy relative to other common chemotherapy regimens for 1 st line treatment of non-small cell lung cancer (NSCLC). METHODS: NSCLC patients initiating 1 st line chemotherapy (pemetrexed/platinum (P/P); carboplatin/paclitaxel + bevacizumab (C/P + B); or carboplatin/paclitaxel (C/P)) from July 1, 2006-June A2 Abstracts 30, 2008 within a large nationwide network of outpatient oncology clinics were studied using US Oncology's iKnowMed EMR. Costs included only those incurred within the network of outpatient oncology clinics and were derived using Medicare reimbursement rates. Patients were matched across regimens on key confounding factors at initiation of treatment: age, stage at diagnosis, ECOG performance status, and comorbidity index. A variable N:M matching ratio was used. Patients were followed through June 30, 2009. A 95% confidence intervals were estimated by bootstrapping (2500 samples) the within-cell differences in cost and time to progression (TTP) of matched patients. RESULTS: A total of 1194 patients were identified: 48 received P/P, 279 received C/P + B, and 867 received C/P. We found that P/P exhibited dominance vs. C/P + B, with higher effectiveness (mean difference in TTP = 1.7 months; CI = 1.1-2.3 months) and lower cost (mean cost difference = −$22,890; CI = $−25,445-$−20,335). Compared to C/P, P/P had higher effectiveness (mean difference in TTP = 2.0 months; CI = 1.7-2.4 months) but also higher costs (mean cost difference = $12,603; CI = $11,579-$13,667) with an incremental cost effectiveness of $6,335/progression-free month (CI = 5, 404) . CONCLUSIONS: This study suggests that P/P may be a cost-effective 1 st line NSCLC treatment in the outpatient community setting. Costs differences were substantial by regimen while differences in TTP were relatively small from a clinical perspective. While this preliminary study utilized conservative analytic methods and controlled for several key confounding factors, future large studies should attempt to further address selection bias and residual confounding. Incident mSCCHN patients between 1993 and 2005 were identified in the SEER-Medicare database using ICD-O codes for primary site and histology with a "distant" tumor in the SEER staging variable. Individuals 65 years or older at the time of diagnosis, with at least 12 months of data preceding initial diagnosis were included. The index date was defined as the date of diagnosis; subjects were followed from 30 days prior to the index date until death or the end of Medicare claims data (December 31, 2007) , whichever occurred first. Chemotherapy use was identified using HCPCS codes. Resource use and health care costs were estimated using the person-years approach to account for patients having different lengths of follow-up. RESULTS: A total of 1420 subjects with mSCCHN were included in this analysis. Mean age was 74 (SD 6.7) years and 70% were males. Mean Charlson comorbidity score without malignancy was 1.4 (SD 1.6) and mean duration of follow-up was 30 months (SD 33). Forty-eight percent of patients received chemotherapy. Carboplatin (18%) was the most commonly used agent followed by paclitaxel (13%) and cisplatin (11%). The mean number of visits per patient per year was 9.7 (SD 10.7) for outpatient care and 2.9 (SD 3.7) for inpatient care. Average annual inpatient days per patient were 31.4 days (SD 51.1). About 40% of the patients received hospice care. Mean total annual health care costs per patient were $155,307, cost of outpatient care constituted 51% and inpatient care 34%. CONCLUSIONS: Inpatient and outpatient costs are the key drivers of total health care costs for patients with mSCCHN.
HE2 HEALTH CARE COSTS OF METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD AND NECK-FINDINGS FROM LINKED SEER-MEDICARE DATA
HE3 CAN INNOVATION BE REWARDED WITH THE APPLICATION OF RIGID COST-EFFECTIVENESS THRESHOLDS? THE HER2+VE BREAST CANCER CASE STUDY
Ray J, Cirrincione A F. Hoffmann-La Roche Ltd., Basel, Switzerland OBJECTIVES: Trastuzumab (Tras) in combination with chemotherapy is the current treatment standard in patients with early and metastatic breast cancer (BC) who are HER2 positive (HER2+). Any regimen under development will have to be compared to Tras both in pivotal clinical trials and during economic assessment. This study raises important policy questions by estimating the feasibility of demonstrating cost-effectiveness (CE) against conventional UK NICE thresholds (£ 20-30,000/QALY gained) for new regimens developed in different lines of treatment for HER2+ BC and incentives for development where rigid thresholds are applied. METHODS: Three CE models were developed using rates of disease progression, survival and efficacy data from 3 Tras clinical trials: HERA for adjuvant, M77001 for 1 st -line metastatic and GBG-26 for 2 nd -line metastatic BC. Isometrics curves were generated for each model whereby each point on the curve corresponded to where the progression-free & overall survival hazard ratios and increase in total costs for the new treatment versus Tras was estimated to result in an ICER of £ 30'000/QALY. Costs and utility values were based on published literature from the UK-NHS perspective. RESULTS: Assuming a 5-year duration of efficacy in early BC (PFS hazard ratio of 0.75), the model estimated that a new treatment could be considered cost-effective with medication acquisition costs 81% above Tras. In the metastatic setting (1 st and 2 nd -line), similar incremental improvements in efficacy, for the OS and PFS hazard ratios over 5 years, suggests that a new regimen could not have medication acquisition costs more than 6-7% above Tras. CONCLUSIONS: Given current treatment costs of the background regimen, it is unlikely that any new combination regimen will be cost-effective using UK thresholds. Results were not sensitive to the magnitude of the incremental survival benefit due to the high correlation between treatment benefit, treatment duration (until cancer progression), and overall treatment costs.
HE4
CHARACTERIZATION OF FREQUENT HOSPITAL EMERGENCY DEPARTMENT (ED) USE BY UN-OR UNDERINSURED PERSONS
Khurshid A 1 , Strassels S 2 1 Integrated Care Collaboration, Austin, TX, USA, 2 University of Texas at Austin, Austin, TX, USA OBJECTIVES: ED use for non-emergencies contributes to crowding, increased health care costs, and, potentially, poor clinical outcomes. Efforts to decrease inappropriate ED use have focused on insured individuals. The purpose of this retrospective cohort study was to characterize frequent ED use among un-and underinsured individuals in central Texas. METHODS: Data were obtained from the ICare system, which includes information for > 800,000 individuals and > 5 million encounters within 24 Central Texas health care providers who arrange for or provide care for uninsured or underinsured individuals. Persons who received care from an ICare-participating organization during calendar year 2007 were included in these analyses. Frequent ED use was defined as at least 6 ED visits within either a calendar quarter or any contiguous three-month period. Linear regression was used to estimate the relation between patient characteristics and total ED visits among frequent users. RESULTS: There were 216,364 ED visits in 2007; 128,538 individuals had at least 1 ED visit and 0.7% (n = 892) were considered frequent ED users. Frequent users were mainly female (55.6%), and Caucasian (55.8%). Hispanics and African-Americans accounted for 14.2% and 17.3% of frequent users, respectively. The regression model accounted for 12.1% of variability in the outcome. Total clinic visits (beta = 0.05, p 0.037, 95% CI 0.003-0.094), inpatient admissions (beta = 1.35, p < 0.001, 95% CI 0.976-1.716) and having any mental health diagnosis in any ED visit (beta = 3.278, p < 0.001. 95% CI 2.060-4.496) were positively and statistically significantly associated with the number of ED visits among frequent users, after adjusting for age, sex, and race. CONCLUSIONS: In 2007, frequent users accounted for < 1% of ED users, and 5.4% of total ED use. A study of these frequent users may help identify opportunities for intervention to help underlying causes for these frequent visits.
PODIUM SESSION I: HEALTH TECHNOLOGY ASSESSMENT STUDIES
HT1
COMPARATIVE-EFFECTIVENESS VERSUS COST-EFFECTIVENESS: A COMPARISON OF THE FRENCH AND SCOTTISH APPROACHES TO SINGLE TECHNOLOGY ASSESSMENT (STA)
Bending MW 1 , Hutton J 1 , McGrath C 2 1 University of York, York, UK, 2 Pfizer, Walton on the Hill, Surrey, UK OBJECTIVES: To compare the pharmaceutical STA guidance advice of Haute Autorité de santé (HAS) which appraises clinical efficacy/safety against the Scottish Medicines Consortium (SMC) in which appraisal includes both clinical and cost-effectiveness. METHODS: All English translated advice were downloaded from the HAS website resulting in 78 transparency committee opinions for between 2005 and 2009. These were matched with SMC advice, resulting in 39 matched drugs. A comparison between drug advice, the clinical evidence through identification of trials on the CENTRAL database of the Cochrane library and a statistical analysis was performed on improvement in medical benefit (ASMR) supplied by HAS and the cost-utility estimates (CQG) of the SMC. RESULTS: The HAS and SMC had the same advice in 14/39 (36%) of the drug comparisons. The average number of trials included were 2 trials in HAS advice and 1.8 trials in SMC advice with more comprehensive detail on the efficacy in HAS advice. Each matched comparison had at least one common trial and 30% of guidance included different additional trials. The correlation between the medical improvement provided by HAS and the SMC CQG were analysed and show that for those treatments considered cost saving by the SMC the ASMR was on average 4.6. The CQG for £0-£10,000 had an average ASMR; 3.6, £10,000-£20,000; 2.8, £20,000-£30,000; 3.1, and £30,000+; 3.4, showing little correlation between ASMR and CQG. CONCLU-SIONS: The differences in guidance advice reflect the countries different HTA processes, interpretation of clinical efficacy and approaches to economics. HAS advice provided more detailed information on the clinical efficacy in comparison to SMC for these drugs. The SMC presented formal analysis of cost-effectiveness in comparison to France where economic issues are considered by the economic committee and not reported. The transparency committee implicitly uses economics as the choice of ASMR influences pricing decisions and the cost-effectiveness of treatments.
